CTOs on the Move

Minaris Advanced Therapies

www.minaris.com

 
Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.minaris.com
  • 400 Rouse Blvd
    Philadelphia, PA USA
  • Phone: +49 89 7009608

Executives

Name Title Contact Details
Luciana Mansolelli
 Chief Quality Officer Profile
Ilya Koltover
 Chief Transformation Officer Profile

Similar Companies

AveXis

AveXis, now a Novartis Company, is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and life-threatening neurological genetic d...

Apthera

Apthera, Inc. is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

BrainScope

BrainScope is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.